Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X:
“Sad to see EA2183 (systemic treatment +/- SBRT for oligomet esophagus/gastric ca) close due to slow accrual after enrolling 27 patients over 5+ years.
If the NCI/NIH wants to decrease research dependence on pharma/industry, need to better incentivize enrollment onto cooperative group trials.”
More posts featuring Nina Niu Sanford.